Literature DB >> 10964295

Osteoradionecrosis of the maxillary-orbital complex after neutron beam radiotherapy.

M T Marunick1, S J Bahu, A Aref.   

Abstract

OBJECTIVE: Neutron beam radiotherapy (NRT) has been advocated for treatment of malignant salivary gland tumors and adenoid cystic carcinoma of the paranasal sinuses. The purpose of this study is to determine whether primary or adjuvant NRT results in a significantly increased rate of osteora-dionecrosis (ORN) of the maxillary-orbital complex (MOC). STUDY DESIGN AND
SETTING: All patients who received primary or adjuvant NRT involving the MOC and/or maxillofacial prosthetic rehabilitation at Wayne State University from 1992 to 1997 were evaluated (n = 9).
RESULTS: ORN did not develop in any of the 5 patients who received primary NRT. All 4 patients who received adjuvant NRT after surgical resection had ORN involving the MOC within the irradiated fields.
CONCLUSION: The reported trend of ORN after definitive surgery and NRT shows a markedly increased complication rate. SIGNIFICANCE: The use of adjuvant NRT after definitive surgical resection involving the MOC should be considered with great caution.

Entities:  

Mesh:

Year:  2000        PMID: 10964295     DOI: 10.1067/mhn.2000.107403

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Head and neck radiotherapy-induced changes in dentomaxillofacial structures detected on panoramic radiographs: A systematic review.

Authors:  Luciana Munhoz; Danielle Ayumi Nishimura; Christyan Hiroshi Iida; Plauto Christopher Aranha Watanabe; Emiko Saito Arita
Journal:  Imaging Sci Dent       Date:  2021-05-06

2.  Dosimetric and Clinical Risk Factors for the Development of Maxillary Osteoradionecrosis in Adenoid Cystic Carcinoma (ACC) Patients Treated With Carbon Ion Radiotherapy.

Authors:  Barbara Vischioni; Stefania Russo; Martino Meuli; Maria Bonora; Sara Ronchi; Rossana Ingargiola; Anna Maria Camarda; Sara Imparato; Lorenzo Preda; Mario Ciocca; Silvia Molinelli; Ester Orlandi
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.